okkkaaayyyyy but if you are real then answer this
" 'Generally' well tolerated" is a major red flag. Toxicity is high with very little efficacy data shown. Sell now before this drops to $3-4. Rebuy after the sell off for Relistor run up. Don't be caught holding this.
SAEs were consistent with phase 1 trial and 2.3 mg/kg dose was more effective and safe than 2.5 mg/kg. If you actually read the abstract "adjustment for tolerability was allowed". the only reason there was a sell-off from the abstract release was because it didn't contain the PFS/OS data. The only thing on retail minds today will be lowered dosage from 2.5 to 2.3 mg/kg because the efficacy data was limited. Management doesn't seem to be to worried about the safety profile of their drug considering that even after full enrollment completion and clinical observations they decided to add an additional cohort of chemo naive patients which costs extra money and infers patients benefiting. I just don't understand why PGNX would extend the trial, drop two PR's within an hour of each other informing shareholders of dual ASCO data presentations and talk to shareholders about the data, if they knew it was going to be a bust and dilute the already depressed share price into the ground. They are in excellent financial condition currently and will more than likely receive sNDA approval for RELISTOR which would add another 50 mill to the balance sheet. I believe the PFS/OS data was left out purposely because management wants to present the meat at ASCO and the mixed shelf offering is going to be used to sell shares from time to time into the increasing volume and price appreciation. There is no reason to dilute the share price even if data is negative. Just my 2 cents.
Management of Progenics Pharmaceuticals has not even issued an official press release on its Phase 2 data from two trials in Prostate Cancer and everybody is "guessing" what are the results !! Many of those who guesses are only interested to create panic to buy the shares.